Homocysteine and Folate Therapy in Dialysis Patients

Author(s): Marco Righetti

Journal Name: Letters in Drug Design & Discovery

Volume 3 , Issue 5 , 2006

Become EABM
Become Reviewer


In the last years scientific interest in homocysteine is growing. Homocysteine is a risk factor for cardiovascular morbidity and mortality in the general population with normal renal function. The relationship between homocysteine and cardiovascular disease in patients with renal failure is unclear. This review shows up homocysteine metabolism and its interactions with drugs and diseases, summarizes homocysteines toxic effects and the results of clinical studies about the effects of homocysteine-lowering therapy on hard endpoints like cardiovascular morbidity and mortality, and describes which kind of treatment can reduce homocysteine in dialysis patients.

Keywords: Homocysteine, folic acid, vitamin B, cardiovascular disease

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [351 - 355]
Pages: 5
DOI: 10.2174/157018006777574140
Price: $65

Article Metrics

PDF: 1